Medivir, Interim Report, 1 January – 31 March 2009

• Net sales were SEK 17.5 (4.2) m.
• The loss after tax was SEK -30.2 (-41.2) m.
• Earnings per share were SEK -1.45 (-1.98).
• Cash flow from operating activities was SEK -41.2 (-5.5) m.
• Liquid assets as of 31 March were SEK 243.1 (323.5) m.


First quarter in brief

Several significant corporate and project events were reported in the quarter.

The highlights can be summarized as follows:

• New data from the phase IIa trial on TMC435 (HCV) will be presented at the EASL’s (European Association for the Study of the Liver) Annual Meeting on 22-26 April.
• The cost review initiated in February is now complete. The target of achieving a cost base of SEK 150 m by the beginning of 2010 will be achievable.
• Another candidate drug (CD) on the cathepsin K project was designated in February, and work on compiling data for forthcoming outlicensing was completed. The process of identifying a partner has begun.


Ron Long
CEO

Huddinge, Sweden, 23 April 2009



For more information, please contact:
Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292 or +46 (0)8 546 83123.


FORTHCOMING FINANCIAL INFORMATION
The AGM will be held today at the Polstjärnan Conference Center, starting at 3 p.m.
The Six-month Interim Report will be published on 9 July 2009.
The Nine-month Interim Report will be published on 21 October 2009.

The Reports will be available at Medivir’s Website, www.medivir.se from this date under the ‘Investor/Media’ heading.